Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-26-023920
Filing Date
2026-05-15
Accepted
2026-05-15 17:01:02
Documents
62
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 725519
2 EX-4.1 ex4-1.htm EX-4.1 110716
3 EX-10.2 ex10-2.htm EX-10.2 151037
4 EX-31.1 ex31-1.htm EX-31.1 12279
5 EX-31.2 ex31-2.htm EX-31.2 12181
6 EX-32.1 ex32-1.htm EX-32.1 5947
7 EX-32.2 ex32-2.htm EX-32.2 5900
8 GRAPHIC form10-q_001.jpg GRAPHIC 7923
  Complete submission text file 0001493152-26-023920.txt   4435351

Data Files

Seq Description Document Type Size
9 XBRL SCHEMA FILE tvgn-20260331.xsd EX-101.SCH 29910
10 XBRL CALCULATION FILE tvgn-20260331_cal.xml EX-101.CAL 38064
11 XBRL DEFINITION FILE tvgn-20260331_def.xml EX-101.DEF 181130
12 XBRL LABEL FILE tvgn-20260331_lab.xml EX-101.LAB 290405
13 XBRL PRESENTATION FILE tvgn-20260331_pre.xml EX-101.PRE 251741
65 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 463072
Mailing Address 15 INDEPENDENCE BOULEVARD, SUITE #210 WARREN NJ 07059
Business Address 15 INDEPENDENCE BOULEVARD, SUITE #210 WARREN NJ 07059 646-807-8832
Tevogen Bio Holdings Inc. (Filer) CIK: 0001860871 (see all company filings)

EIN.: 981597194 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41002 | Film No.: 26989483
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)